NDAORALTABLET
Approved
Jan 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
TASMAR (tolcapone) by Bausch + Lomb is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 1998.
Drug data last refreshed 4h ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TASMAR (tolcapone) is an oral catechol-O-methyltransferase (COMT) inhibitor approved in 1998 for Parkinson's disease. It works by inhibiting the enzyme responsible for breaking down levodopa, thereby extending dopamine availability in the brain and improving motor control. Tolcapone is used as an adjunctive therapy to levodopa/carbidopa in patients experiencing motor fluctuations.
$0.2MPart D
LOE ApproachingMinimal commercial activity with only $201K in Part D spending and 13 claims suggests a mature, niche product with limited team expansion potential.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)
Started Oct 2018
10 enrolled
Transthyretin AmyloidosisAmyloidosis, Leptomeningeal, Transthyretin-Related
A Study Assessing the Safety and Pharmacokinetic Profile of Modified Release Formulations of Tolcapone
Started Jun 2018
12 enrolled
Healthy Volunteers
Career Relevance
TASMAR presents minimal career growth opportunities given its mature, niche market status and LOE-approaching lifecycle. Roles associated with this product are typically small, stable, and focused on defending existing market share rather than innovation or expansion.
Worked on TASMAR at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.